Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Operations Remain Suspended at Many Drug Production Facilities 1 Week after Disaster
March 28, 2011
- Nomura Securities Expects Peak Sales of ¥130 Bil. for Latuda
March 28, 2011
- Chuikyo Meetings to Be Postponed Due to Disaster
March 28, 2011
- Takeda Suspends Shipment of All ASKA Pharma Products
March 28, 2011
- Astellas Settles Dispute over Tarceva Patents with Teva
March 28, 2011
- JAMS Cancels 2011 General Assembly
March 28, 2011
- Fuso's Replacement Fluid in Short Supply
March 28, 2011
- Sales by Member Companies Up 0.2% in 2010: JCROA
March 28, 2011
- Most Scientific Meetings Postponed or Cancelled
March 28, 2011
- Maintain Electric Power to Ensure Stable Drug Supply: FPMAJ
March 28, 2011
- Drugstore Sales Up 3.5% in FY2010: JACDS
March 28, 2011
- Change in Prescription Form Proposed by JSGM President
March 28, 2011
- Requests for Frequent Delivery Abating in Tohoku: Wholesalers
March 28, 2011
- Oncology Strategies of Top-four Japanese Pharmaceutical Companies
March 28, 2011
- Nichi-Iko Acquires Additional Shares from Aprogen
March 28, 2011
- JSMI Presents List of OTC Drugs Available Free of Charge
March 28, 2011
- Takeda Suspends PII Trial for Anti-obesity Drug in US
March 28, 2011
- 14 Hokoku-hinmoku Included in NHI Price List
March 28, 2011
- MTPC Ties Up with Kyoto Univ. to Develop Drugs for Kidney Disease
March 28, 2011
- Korosho Calls For Reasonable Ordering Practices from Med. Institutions, Pharmacies
March 28, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…